Do standardized hip fracture care programs decrease mortality in geriatric hip fracture patients?

There is mounting support for the implementation of a standardized hip fracture program (SHFP) for geriatric patients. However, the current evidence to assess geriatric hip fracture outcomes following treatment in a SHFP is limited to small, single-center, observational studies. Using a large, multinational dataset, this study aims to assess whether enrollment in a SHFP was associated with improved 30-day patient-important outcomes in geriatric hip fracture patients. The secondary aim was to evaluate if the SHFP treatment effect varies by baseline mortality risk. An observational cohort study was conducted using data from the National Surgical Quality Improvement Program (NSQIP) for the years of 2016 and 2017. The study included 17,395 geriatric hip fracture patients over the age of 65. Over half (54%) of patients were enrolled in a SHFP on admission to hospital. The primary outcome was 30-day mortality. Secondary outcomes included 30-day reoperation and readmission. Multivariable logistic regression was used to estimate treatment effects, adjusting for race, anesthesia technique, and baseline mortality risk. The heterogeneity of treatment effect was determined by stratifying patients into quartiles based on their baseline mortality risk. The overall 30-day mortality risk was 6.6%. Enrollment in a SHFP did not reduce the 30-day risk of mortality (risk difference (RD): -0.2; 95% CI: -0.7, 0.3; p = 0.48), reoperation (RD: -0.2%; 95% CI: -0.6, 0.3; p = 0.36) or readmission (RD: -0.4%; 95% CI: -0.1, 0.4%; p = 0.20) when analyzed as a single sample. However, there were greater differences in the SHFP treatment effects when stratified by their preoperative mortality risk. Specifically, a 2.0% (95% CI: 4.2, 0.0%; p = 0.06) reduction in mortality was observed in the patients in the highest risk quartile for mortality and a 1.7% (95% CI: -3.2, -0.2%; p = 0.02) reduction in the medium-high risk quartile. The NSQIP data suggest that SHFPs do not significantly improve the short-term outcomes for the average geriatric hip fracture patient. However, a SHFP may significantly reduce the risk of 30-day mortality in higher risk patients. Therefore, the efficiency of SHFPs could potentially be improved with targeted deployment to high risk geriatric hip fracture patients.